BMO Capital analyst Keith Tapper reiterated an Outperform rating and $60.00 price target on Neurogene (NASDAQ: NGNE).The analyst commented, "The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE